IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells

Noriko Ogasawara; Julie A. Poposki; Aiko I. Klingler; Bruce K. Tan; Ava R. Weibman; Kathryn E. Hulse; Whitney W. Stevens; Anju T. Peters; Leslie C. Grammer; Robert P. Schleimer; Kevin C. Welch; Stephanie S. Smith; David B. Conley; Joseph R. Raviv; Pejman Soroosh; Omid Akbari; Tetsuo Himi; Robert C. Kern; Atsushi Kato

doi:10.1016/j.jaci.2017.09.025

IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells

Noriko Ogasawara, Julie A. Poposki, Aiko I. Klingler, Bruce K. Tan, Ava R. Weibman, Kathryn E. Hulse, Whitney W. Stevens, Anju T. Peters, Leslie C. Grammer, Robert P. Schleimer, Kevin C. Welch, Stephanie S. Smith, David B. Conley, Joseph R. Raviv, Pejman Soroosh, Omid Akbari, Tetsuo Himi, Robert C. Kern, Atsushi Kato

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Original language	English (US)
Pages (from-to)	1147-1151.e8
Journal	Journal of Allergy and Clinical Immunology
Volume	141
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2017.09.025
State	Published - Mar 2018

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2017.09.025

Cite this

Ogasawara, N., Poposki, J. A., Klingler, A. I., Tan, B. K., Weibman, A. R., Hulse, K. E., Stevens, W. W., Peters, A. T., Grammer, L. C., Schleimer, R. P., Welch, K. C., Smith, S. S., Conley, D. B., Raviv, J. R., Soroosh, P., Akbari, O., Himi, T., Kern, R. C., & Kato, A. (2018). IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. Journal of Allergy and Clinical Immunology, 141(3), 1147-1151.e8. https://doi.org/10.1016/j.jaci.2017.09.025

Ogasawara, Noriko ; Poposki, Julie A. ; Klingler, Aiko I. ; Tan, Bruce K. ; Weibman, Ava R. ; Hulse, Kathryn E. ; Stevens, Whitney W. ; Peters, Anju T. ; Grammer, Leslie C. ; Schleimer, Robert P. ; Welch, Kevin C. ; Smith, Stephanie S. ; Conley, David B. ; Raviv, Joseph R. ; Soroosh, Pejman ; Akbari, Omid ; Himi, Tetsuo ; Kern, Robert C. ; Kato, Atsushi. / IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. In: Journal of Allergy and Clinical Immunology. 2018 ; Vol. 141, No. 3. pp. 1147-1151.e8.

@article{b47ffddff84147b4a6f58786973d4dbd,

title = "IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells",

author = "Noriko Ogasawara and Poposki, {Julie A.} and Klingler, {Aiko I.} and Tan, {Bruce K.} and Weibman, {Ava R.} and Hulse, {Kathryn E.} and Stevens, {Whitney W.} and Peters, {Anju T.} and Grammer, {Leslie C.} and Schleimer, {Robert P.} and Welch, {Kevin C.} and Smith, {Stephanie S.} and Conley, {David B.} and Raviv, {Joseph R.} and Pejman Soroosh and Omid Akbari and Tetsuo Himi and Kern, {Robert C.} and Atsushi Kato",

note = "Funding Information: We gratefully acknowledge Dr Suchitra Swaminathan and the Flow Cytometry Core Facility, supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, for their technical assistance during cell sorting. Flow Cytometry Cell Sorting was performed on a BD FACSAria SORP system, purchased through the support of the National Institutes of Health (grant no. 1S10OD011996-01). We also acknowledge Ms Lydia Suh, Mr James Norton, Mr Roderick Carter, Ms Caroline P. E. Price, and Ms Kathleen E. Harris (Northwestern University Feinberg School of Medicine) for their skillful technical assistance. Funding Information: Disclosure of potential conflict of interest: J. A. Poposki's institution received a grant from the National Institutes of Health (NIH) (grant no. R01AI104733) for this work and other works. B. K. Tan's institution received a grant from the NIH (grant no. U19 AI106683) for this work. W. Q. Stevens personally received a grant from Parker B. Francis Fellowship Program, the American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma & Immunology (AAAAI) HOPE Pilot Grant Award, and KL-2 Award for this work. L. C. Grammer's institute received a grant and support for travel from the NIH and a grant from Bazley Foundation grant for this work; the institution received grants from the NIH, the Food Allergy Network, and the Bazley Foundation for other works. L. C. Grammer personally received consultancy fees from Astellas Pharmaceuticals; is employed by Northwestern University and Northwestern Medical Faculty Foundation; received payment for lectures from the AAAAI, Mount Sinai, New York, NY; and receives royalties from the AAAAI, Mount Sinai. R. P. Schleimer's institution received a grant from the NIH. R. P. Schleimer personally received consultancy fees from Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/Medimmune, Genentech, Exicure Inc, Otsuka Inc, and Aqualung Therapeutics Corp; received stock options from Allakos, Aurasense, BioMarck, Exicure Inc, and Aqualung Therapeutics Corp. S. S. Smith's institution received Triological Society Career Development Award for this work; she is employed by Northwestern Medicine/Northwestern University. P. Soroosh is employed by Janssen Immunology. O. Akbari's institute received a grant from the NIH for this work. A. Kato's institution received grants from the NIH (grant nos. R01AI104733, U19AI106683, and R37HL068546) and Janssen Research Fund for this work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This research was supported in part by the National Institutes of Health (grant nos. R01 AI104733, R37HL068546, and U19 AI106683) and by grants from the Janssen Research Fund and the Ernest S. Bazley Foundation. ",

year = "2018",

month = mar,

doi = "10.1016/j.jaci.2017.09.025",

language = "English (US)",

volume = "141",

pages = "1147--1151.e8",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "3",

}

Ogasawara, N, Poposki, JA, Klingler, AI, Tan, BK, Weibman, AR, Hulse, KE, Stevens, WW , Peters, AT , Grammer, LC , Schleimer, RP , Welch, KC , Smith, SS , Conley, DB, Raviv, JR, Soroosh, P, Akbari, O, Himi, T, Kern, RC & Kato, A 2018, 'IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells', Journal of Allergy and Clinical Immunology, vol. 141, no. 3, pp. 1147-1151.e8. https://doi.org/10.1016/j.jaci.2017.09.025

IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. / Ogasawara, Noriko; Poposki, Julie A.; Klingler, Aiko I.; Tan, Bruce K.; Weibman, Ava R.; Hulse, Kathryn E.; Stevens, Whitney W.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Raviv, Joseph R.; Soroosh, Pejman; Akbari, Omid; Himi, Tetsuo; Kern, Robert C.; Kato, Atsushi.

In: Journal of Allergy and Clinical Immunology, Vol. 141, No. 3, 03.2018, p. 1147-1151.e8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells

AU - Ogasawara, Noriko

AU - Poposki, Julie A.

AU - Klingler, Aiko I.

AU - Tan, Bruce K.

AU - Weibman, Ava R.

AU - Hulse, Kathryn E.

AU - Stevens, Whitney W.

AU - Peters, Anju T.

AU - Grammer, Leslie C.

AU - Schleimer, Robert P.

AU - Welch, Kevin C.

AU - Smith, Stephanie S.

AU - Conley, David B.

AU - Raviv, Joseph R.

AU - Soroosh, Pejman

AU - Akbari, Omid

AU - Himi, Tetsuo

AU - Kern, Robert C.

AU - Kato, Atsushi

N1 - Funding Information: We gratefully acknowledge Dr Suchitra Swaminathan and the Flow Cytometry Core Facility, supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, for their technical assistance during cell sorting. Flow Cytometry Cell Sorting was performed on a BD FACSAria SORP system, purchased through the support of the National Institutes of Health (grant no. 1S10OD011996-01). We also acknowledge Ms Lydia Suh, Mr James Norton, Mr Roderick Carter, Ms Caroline P. E. Price, and Ms Kathleen E. Harris (Northwestern University Feinberg School of Medicine) for their skillful technical assistance. Funding Information: Disclosure of potential conflict of interest: J. A. Poposki's institution received a grant from the National Institutes of Health (NIH) (grant no. R01AI104733) for this work and other works. B. K. Tan's institution received a grant from the NIH (grant no. U19 AI106683) for this work. W. Q. Stevens personally received a grant from Parker B. Francis Fellowship Program, the American Partnership for Eosinophilic Disorders/American Academy of Allergy, Asthma & Immunology (AAAAI) HOPE Pilot Grant Award, and KL-2 Award for this work. L. C. Grammer's institute received a grant and support for travel from the NIH and a grant from Bazley Foundation grant for this work; the institution received grants from the NIH, the Food Allergy Network, and the Bazley Foundation for other works. L. C. Grammer personally received consultancy fees from Astellas Pharmaceuticals; is employed by Northwestern University and Northwestern Medical Faculty Foundation; received payment for lectures from the AAAAI, Mount Sinai, New York, NY; and receives royalties from the AAAAI, Mount Sinai. R. P. Schleimer's institution received a grant from the NIH. R. P. Schleimer personally received consultancy fees from Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/Medimmune, Genentech, Exicure Inc, Otsuka Inc, and Aqualung Therapeutics Corp; received stock options from Allakos, Aurasense, BioMarck, Exicure Inc, and Aqualung Therapeutics Corp. S. S. Smith's institution received Triological Society Career Development Award for this work; she is employed by Northwestern Medicine/Northwestern University. P. Soroosh is employed by Janssen Immunology. O. Akbari's institute received a grant from the NIH for this work. A. Kato's institution received grants from the NIH (grant nos. R01AI104733, U19AI106683, and R37HL068546) and Janssen Research Fund for this work. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This research was supported in part by the National Institutes of Health (grant nos. R01 AI104733, R37HL068546, and U19 AI106683) and by grants from the Janssen Research Fund and the Ernest S. Bazley Foundation.

PY - 2018/3

Y1 - 2018/3

UR - http://www.scopus.com/inward/record.url?scp=85034967997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034967997&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2017.09.025

DO - 10.1016/j.jaci.2017.09.025

M3 - Article

C2 - 29074458

AN - SCOPUS:85034967997

VL - 141

SP - 1147-1151.e8

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -

IL-10, TGF-β and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this